{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T10:05:40Z","timestamp":1760954740912},"reference-count":42,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2005,3,1]],"date-time":"2005-03-01T00:00:00Z","timestamp":1109635200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2005,3]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Background<\/jats:bold> :\u2002New methods to estimate the systemic exposure to ciclosporin such as the level 2\u2003h after dosing and limited sampling formulas may lead to improved clinical outcome after orthotopic liver transplantation. However, most strategies are characterized by rigid sampling times.<\/jats:p><jats:p><jats:bold>Aim<\/jats:bold> :\u2002To develop and validate a flexible individualized population\u2010pharmacokinetic model for ciclosporin monitoring in orthotopic liver transplantation.<\/jats:p><jats:p><jats:bold>Methods<\/jats:bold> :\u2002A total of 62 curves obtained from 31 patients at least 0.5\u2003year after orthotopic liver transplantation were divided into two equal groups. From 31 curves, relatively simple limited sampling formulas were derived using multiple regression analysis, while using pharmacokinetic software a two\u2010compartment population\u2010pharmacokinetic model was derived from these same data. We then tested the ability to estimate the <jats:italic>AUC<\/jats:italic> by the limited sampling formulas and a different approach using several limited sampling strategies on the other 31 curves. The new approach consists of individualizing the mean <jats:italic>a priori<\/jats:italic> population\u2010pharmacokinetic parameters of the two\u2010compartment population\u2010pharmacokinetic model by means of maximum <jats:italic>a posteriori<\/jats:italic> Bayesian fitting with individual data leading to an individualized population\u2010pharmacokinetic limited sampling model. From the individualized pharmacokinetic parameters, <jats:italic>AUC<\/jats:italic><jats:sub>0\u201012h<\/jats:sub> was calculated for each combination of measured blood concentrations. The calculated <jats:italic>AUC<\/jats:italic><jats:sub>0\u201012h<\/jats:sub> both from the limited\u2010sampling formulas and the limited\u2010sampling model were compared with the gold standard <jats:italic>AUC<\/jats:italic><jats:sub>0\u201012h<\/jats:sub> (trapezoidal rule) by Pearson's correlation coefficient and prediction precision and bias were calculated.<\/jats:p><jats:p><jats:bold>Results<\/jats:bold> :\u2002The <jats:italic>AUC<\/jats:italic><jats:sub>0\u201012h<\/jats:sub> value calculated by individualizing the population\u2010pharmacokinetic model using several combinations of measured blood concentrations: 0\u2003+\u20032\u2003h (<jats:italic>r<\/jats:italic><jats:sup>2<\/jats:sup>\u2003=\u20030.94), 0\u2003+\u20031\u2003+\u20032\u2003h (<jats:italic>r<\/jats:italic><jats:sup>2<\/jats:sup>\u2003=\u20030.94), 0\u2003+\u20031\u2003+\u20033\u2003h (<jats:italic>r<\/jats:italic><jats:sup>2<\/jats:sup>\u2003=\u20030.92), 0\u2003+\u20032\u2003+\u20033\u2003h (<jats:italic>r<\/jats:italic><jats:sup>2<\/jats:sup>\u2003=\u20030.92) and 0\u2003+\u20031\u2003+ 2\u2003+\u20033\u2003h (<jats:italic>r<\/jats:italic><jats:sup>2<\/jats:sup>\u2003=\u20030.96) had excellent correlation with <jats:italic>AUC<\/jats:italic><jats:sub>0\u201012h<\/jats:sub>, better than limited sampling formulas with less than three sampling time points. Even trough level with limited sampling method (<jats:italic>r<\/jats:italic><jats:sup>2<\/jats:sup>\u2003=\u20030.86) correlated better than the level after 2\u2003h of dosing (<jats:italic>r<\/jats:italic><jats:sup>2<\/jats:sup>\u2003=\u20030.75) or trough level (<jats:italic>r<\/jats:italic><jats:sup>2<\/jats:sup>\u2003=\u20030.64) as single values without limited sampling method. Moreover, the individualized population\u2010pharmacokinetic model had a low prediction bias and excellent precision.<\/jats:p><jats:p><jats:bold>Conclusion<\/jats:bold> :\u2002Multiple rigid sampling time points limit the use of limited sampling formulas. The major advantage of the Bayesian estimation approach presented here, is that blood sampling time points are not fixed, as long as sampling time is known. The predictive performance of this new approach is superior to trough level and that after 2\u2003h of dosing and at least as good as limited sampling formulas. It is of clear advantage in busy out\u2010patient clinics.<\/jats:p>","DOI":"10.1111\/j.1365-2036.2005.02364.x","type":"journal-article","created":{"date-parts":[[2005,3,1]],"date-time":"2005-03-01T09:48:39Z","timestamp":1109670519000},"page":"549-557","source":"Crossref","is-referenced-by-count":13,"title":["Easy\u2010to\u2010use, accurate and flexible individualized Bayesian limited sampling method without fixed time points for ciclosporin monitoring after liver transplantation"],"prefix":"10.1111","volume":"21","author":[{"given":"P.","family":"Langers","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. C. L. M.","family":"Cremers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"den Hartigh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. M. T.","family":"Rijnbeek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Ringers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. B. H. W.","family":"Lamers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"van Hoek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,3]]},"reference":[{"key":"e_1_2_14_2_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200161130-00006"},{"key":"e_1_2_14_3_2","doi-asserted-by":"publisher","DOI":"10.2165\/00063030-200115050-00001"},{"key":"e_1_2_14_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200205151-00002"},{"key":"e_1_2_14_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199912270-00003"},{"key":"e_1_2_14_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2003.08.008"},{"key":"e_1_2_14_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200205151-00004"},{"key":"e_1_2_14_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200205151-00003"},{"key":"e_1_2_14_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199812270-00009"},{"key":"e_1_2_14_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199904270-00008"},{"key":"e_1_2_14_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0041-1345(01)02317-X"},{"key":"e_1_2_14_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0041-1345(01)02316-8"},{"key":"e_1_2_14_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0041-1345(01)02318-1"},{"key":"e_1_2_14_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0041-1345(02)03009-9"},{"key":"e_1_2_14_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200203270-00022"},{"key":"e_1_2_14_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/lt.20056"},{"key":"e_1_2_14_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199559040-00011"},{"key":"e_1_2_14_18_2","volume-title":"TTN. Clinical Pharmacokinetics, Concepts and Applications","author":"Rowland M","year":"1989"},{"key":"e_1_2_14_19_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199834010-00003"},{"key":"e_1_2_14_20_2","first-page":"531","article-title":"Adaptive control of drug dosage regimens using maximum a posteriori probability Bayesian fitting","volume":"33","author":"Proost JH.","year":"1995","journal-title":"Int J Clin Pharmacol Ther"},{"key":"e_1_2_14_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01060893"},{"key":"e_1_2_14_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(02)85038-X"},{"key":"e_1_2_14_23_2","doi-asserted-by":"publisher","DOI":"10.1373\/49.5.813"},{"key":"e_1_2_14_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200212270-00027"},{"key":"e_1_2_14_25_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-1007375"},{"key":"e_1_2_14_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840140424"},{"key":"e_1_2_14_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(12)60022-6"},{"key":"e_1_2_14_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510280306"},{"key":"e_1_2_14_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200201270-00027"},{"key":"e_1_2_14_30_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-6143.2002.020206.x"},{"key":"e_1_2_14_31_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-6143.2002.020207.x"},{"key":"e_1_2_14_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0041-1345(00)00864-2"},{"key":"e_1_2_14_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/lt.20070"},{"key":"e_1_2_14_34_2","doi-asserted-by":"publisher","DOI":"10.1089\/10799900152434385"},{"key":"e_1_2_14_35_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200002150-00022"},{"key":"e_1_2_14_36_2","doi-asserted-by":"publisher","DOI":"10.1109\/TBME.2003.809498"},{"key":"e_1_2_14_37_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200241010-00006"},{"key":"e_1_2_14_38_2","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s00228-003-0559-5","article-title":"Limited sampling strategies using Bayesian estimation or multilinear regression for cyclosporin AUC(0\u201312) monitoring in cardiac transplant recipients over the first year post\u2010transplantation","volume":"58","author":"Monchaud C","year":"2003","journal-title":"Eur J Clin Pharmacol"},{"key":"e_1_2_14_39_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200140050-00004"},{"key":"e_1_2_14_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2004.01.009"},{"key":"e_1_2_14_41_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-200104000-00003"},{"key":"e_1_2_14_42_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-200402000-00006"},{"key":"e_1_2_14_43_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfg065"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2005.02364.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2005.02364.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T21:07:29Z","timestamp":1697231249000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2005.02364.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,3]]}},"alternative-id":["10.1111\/j.1365-2036.2005.02364.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2005.02364.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,3]]}}}